冠心宁对冠心病稳定性心绞痛患者血清ICAM-1、VCAM-1和miR-21的影响分析  

Effects of Guanxinning Tablet on serum intercellular adhesion molecule-1,vascular cell adhesion molecule-1,microRNA-21 in patients with stable angina pectoris of coronary heart disease

作　　者：姜爱燕 徐冬[1] JIANG Ai-yan;XU Dong(Pharmacy Zhejiang Medical and Health Group Quzhou Hospital(Zhejiang Quhua Hospital),Zhejiang 324000,China)

机构地区：[1]浙江省医疗健康集团衢州医院(浙江衢化医院)药剂科,浙江324000

出　　处：《中国卫生检验杂志》2023年第16期1975-1978,1982,共5页Chinese Journal of Health Laboratory Technology

基　　金：浙江省医学会临床科研基金项目(2021ZYC-A215);浙江省医学会临床科研基金项目(2021ZYC-A216);正大青春宝中成药新药科研专项(2020ZYC-A88)。

摘　　要：目的分析冠心宁对冠心病稳定性心绞痛患者血清细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)和microRNA-21(miR-21)的影响。方法回顾性选取本院2020年7月—2022年8月收治的冠心病稳定性心绞痛患者142例为研究对象,其中行常规用药治疗的患者69例为对照组,治疗方案在对照组的基础上联合使用冠心宁的患者73例为观察组。2组均完成4周的治疗后,分别检测记录患者血液流变学指标、血清ICAM-1、VCAM-1和miR-21水平、血压、心率、心绞痛发作情况、临床疗效及不良反应发作情况。结果2组患者治疗后各指标均得到改善(P<0.05)。行组间数据比较结果显示,观察组的中药症候积分下降,临床疗效好于对照组(P<0.05);观察组的血液流变学指标,包括血浆黏度、全血黏度低切、全血黏度高切均低于对照组(P<0.05);观察组血压及心率下降较对照组明显(P<0.05);组间心绞痛发作情况比较,观察组心绞痛发作频次小于对照组,持续时间短于对照组(P<0.05);观察组血清ICAM-1、VCAM-1及miR-21水平低于对照组,差异均有统计学意义(P<0.05)。结论冠心宁可以显著提高对冠心病稳定性心绞痛患者的疗效,缓解心绞痛发作,预防冠状动脉粥样硬化,且安全性良好。Objective This paper aims to analyze the effects of Guanxinning Tablet on serum intercellular adhesion molecule-1(ICAM-1),vascular cell adhesion molecule-1(VCAM-1)and microRNA-21(miR-21)in patients with stable angina pectoris.Methods A total of 142 patients with stable angina pectoris admitted to our hospital from July 2020 to August 2022 were retrospectively selected as the study objects,among which 69 patients receiving conventional drug treatment were set as the control group,and 73 patients receiving combined treatment with Guanxining Tablet on the basis of the control group were set as the observation group.After 4 weeks of treatment,hemorheology indexes,serum levels of ICAM-1,VCAM-1 and miR-21,blood pressure,heart rate,angina attacks,clinical efficacy and adverse reactions were detected and recorded in both groups,respectively.Results All indexes of the two groups were improved after treatment(P<0.05).The results of data comparison between the two groups showed that the TCM syndrome score of the observation group decreased,and the clinical efficacy was better than that of the control group(P<0.05).The hemorheology indexes in the observation group,including plasma viscosity,whole blood viscosity low cut and whole blood viscosity high cut,were lower than those in the control group(P<0.05).The blood pressure and heart rate of the observation group decreased than those of the control group(P<0.05).The frequency and duration of angina in the observation group were lower than those in the control group(P<0.05).The levels of ICAM-1,VCAM-1 and miR-21 in the observation group were lower than those in the control group(P<0.05).Conclusion Guanxinning Tablet has significant efficacy for patients with stable angina pectoris,relieve angina pectoris attack,prevent coronary atherosclerosis,and has good safety.

关 键 词：冠心宁片 冠心病 稳定性心绞痛 细胞间黏附分子-1 血管细胞黏附分子-1 MICRORNA-21 

分 类 号：R541.4[医药卫生—心血管疾病]